Rivas MC, et al. - In unresectable locally advanced stage III non-small cell lung cancer (NSCLC), researchers assessed the activity as well as safety of the combination of cisplatin and vinorelbine with thoracic radiotherapy. With a manageable safety profile, this combined regimen was found to be effective and provided encouraging progression-free survival (PFS) and overall survival (OS) outcomes.

Methods

• Study included 48 NSCLC patients (median age 60 years, 52% stage IIIA and 48% stage IIIB, 52% adenocarcinoma).
• Three cycles of chemotherapy every 21 days (intravenous cisplatin 80 mg/m2 and intravenous vinorelbine 25 mg/m² on day 1 and oral vinorelbine on day 8 [60 mg/m²]) concurrent with radiotherapy (66 Gy, administered at 1.8 Gy per day, five consecutive days per week) was given to patients.

Results

• As per findings, objective response rate was 79.2% (72.9% showing partial response and 6.3% showing complete response).
• A median PFS of 12 months and median OS of 36 months after a median follow-up of 20.7 months.
• Neutropenia (14.5%), anemia (6.2%), vomiting (2%), and esophagitis (4.2%) were the grade 3/4 toxicities cited, with no toxic deaths.